BVS vs MCK: fair value comparison
Bioventus Inc. and McKesson Corporation · Updated 2026-09-06
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, MCK currently sits closer to the top of our discount ranking. BVS carries the stronger quality grade.
| BVS | MCK | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $13.47 | $907.99 |
| 12-month range | $6.56–$13.47 | $734.82–$990.95 |
| Sector rank | #85 of 113 Healthcare | #80 of 113 Healthcare |
| Quality grade | D | F |
| Leverage | Moderate | Low |
| Margin trend | — | Stable |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BVS fair value analysis · MCK fair value analysis